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ABSTRACT:   
Objectives. Regulatory T cells (Tregs) are instrumental for tolerance to self-antigens and 
dietary proteins. We have previously shown that IL-15, a cytokine overexpressed in the 
intestine of patients with celiac disease (CD), does not impair the generation of functional 
Tregs but renders human T cells resistant to Treg suppression. Treg numbers and responses of 
intestinal and peripheral T lymphocytes to suppression by Tregs were therefore compared in 
CD patients and controls.  
Methods. Intraepithelial lymphocytes (IEL) and lamina propria lymphocytes (LPL) were 
isolated from duodenal biopsies of CD patients and controls. Concomitantly, CD4+CD25+ T 
lymphocytes (Tregs) were purified from blood. Responses of IEL and of LPL and PBL to 
suppression by Tregs were tested by analysing anti-CD3-induced proliferation and IFN-γ 
production in the presence or not of peripheral Tregs. Lamina propria and peripheral 
CD4+CD25+FOXP3+ T cells were assessed by flow cytometry. 
Results. While percentages of CD4+CD25+FOXP3+ LPL were significantly increased in 
patients with active CD, proliferation and IFN-γ production of intestinal T lymphocytes were 
significantly less inhibited by autologous or heterologous Tregs in CD patients than in 
controls (p< 0.01). In all tested CD patients, IEL were unable to respond to Tregs. Resistance 
of LPL and PBL to Tregs suppression was observed in patients with villous atrophy who had 
serum levels of IL-15 significantly enhanced compared to patients without villous atrophy and 
to controls.  
Conclusion. Our results indicate that effector T lymphocytes from active CD become 
resistant to suppression by Tregs. This resistance might cause loss of tolerance to gluten but 
also to self-antigens.   
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Study highlights: 
 
 
WHAT IS CURRENT KNOWLEDGE: 
 
 IL-15 is overexpressed in the intestine of celiac disease patients. 
 One important mechanism to achieve and maintain tolerance to dietary proteins relies on the 
generation and activation of CD4+CD25+FOXP3+ T regulatory cells.  
 IL-15 renders in vitro conventional lymphocytes resistant to suppressive functions of 
regulatory T cells. 
 In active celiac disease, regulatory T cells are increased in the intestine and can suppress 
activation of conventional lymphocytes.  
 
WHAT IS NEW HERE: 
 
 Suppression of lamina propria T lymphocytes by peripheral autologous and heterologous 
Tregs is impaired in celiac disease patients and the level of inhibition varies depending on the 
presence or not of intestinal lesions.  
 Intraepithelial lymphocytes of both active and treated celiac disease patients are resistant to 
the inhibitory effects of peripheral Tregs. 
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INTRODUCTION 
Celiac disease (CD) is a small intestinal enteropathy induced by cereal-derived 
prolamins (gluten) in genetically susceptible individuals. Activation of lamina propria 
gliadin-specific CD4+ T cells is a keystone of CD pathogenesis and results from the selective 
interplay between prolamins, the triggering environmental factor, and HLA-DQ2/8 molecules, 
the main genetic risk factor (1). This mechanism, although necessary, is however not 
sufficient to explain the loss of tolerance to dietary gluten in only a subset of individuals with 
at risk HLA. Furthermore, humanized mice engineered to express human HLA-DQ8 mount 
efficient CD4+ responses to gluten but do not develop intestinal lesions (2). One important 
mechanism to achieve and maintain tolerance to dietary proteins relies on the generation and 
activation of CD4+CD25+FOXP3+ T regulatory cells (Tregs), a subset of lymphocytes 
initially identified by Sakaguchi in mice for their role against autoimmunity (reviewed in (3)). 
In humans, patients with mutations affecting the FOXP3 gene and lacking functional Tregs 
develop severe autoimmune diseases (4,5) but also dramatic food allergy (6). In mice, antigen 
feeding induce specific Tregs in gut-associated lymphoid tissues and in lamina propria 
(reviewed in (7)) and the depletion of such cells results in the loss of intestinal and peripheral 
tolerance to the corresponding food antigen (8). No genetic link of CD with the FOXP3 gene 
has been observed (9) and previous studies have suggested that the number of lymphocytes 
with a Treg phenotype, evaluated in the peripheral blood by flow cytometry (10,11) and in the 
intestine by immunohistochemistry (12-15) was increased. Recent findings, however, indicate 
that IL-15, a cytokine overexpressed in the intestine and in the serum of active CD patients 
(16-18), might, at least in combination with retinoic acid, hamper in vitro generation of mouse 
Tregs in the presence of dendritic cells (19). Contrasting with the later finding, we have 
observed that IL-15 did not impair but rather promoted the generation of functional human 
Tregs in an in vitro assay without dendritic cells (20). Yet, following pre-incubation in the 
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presence of IL-15, human peripheral T lymphocytes became resistant to the suppressive 
functions of Tregs, a resistance that resulted from PI3 kinase activation (20). Altogether, these 
conflicting data led us to reevaluate by flow cytometry the numbers of Tregs in the peripheral 
blood and in the lamina propria of CD patients and, subsequently, to investigate the responses 
of intestinal and peripheral T cells of CD patients to Treg immunosuppressive effects. 
 
MATERIAL AND METHODS 
Patients and Controls 
Twenty-four adult patients (age range, 22–50 years; mean age, 35 years) had 
uncomplicated CD. The diagnosis was based on detection of villous atrophy and anti-
endomysium/transglutaminase antibodies. At the time of study, 15 patients had active CD 
with partial to total villous atrophy and 9 were on a gluten free diet (GFD). Six of the later 
patients strictly adhered to GFD (3 months – 7 years; mean, 4 years), had normal villous 
architecture and were negative for anti-endomysium antibodies, while three were partially 
compliant to the diet (4 months – 3 years; mean, 2 years), had areas of mild partial villous 
atrophy on all or some biopsy specimens and were positive for celiac antibodies (IgA anti-
endomysium and anti-transglutaminase). All biopsies were obtained during endoscopy 
performed for diagnosis or follow-up purposes. Twenty-two patients were included as 
controls (age range, 30–37 years; mean, 41 years). These patients, with no family history of 
CD or other autoimmune diseases, underwent gastro-duodenal endoscopy for diagnostic 
purposes and had histologically normal small intestinal samples. Informed consent was 
obtained from all patients before the study. All experiments were approved by local ethics 
committee (Institute Pasteur of Tunis).  
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Lymphocyte Isolation  
IELs and LPL were isolated from endoscopic samples as previously described (21, 
22). Yield from biopsies was 0.3-0.8 x 106 for IEL and 0.5-1.3 x 106 for LPL. CD25 negative 
cells (0.35 to 1.1 x 106) were recovered from LPL after negative selection using magnetic 
beads (CD25 microbeads, Miltenyi Biotec, Bergisch-Gladbach, Germany). Peripheral blood 
mononuclear cells (PBMC) were isolated on Ficoll-Hypaque gradient. For co-culture 
experiments, CD4+CD25+ (Tregs) and CD4+CD25- T cells were isolated in a two-step 
procedure using the CD4+CD25+ regulatory T-cell isolation kit (Miltenyi Biotec) according 
to manufacturer’s instructions. Peripheral Tregs were collected with a purity ranging from 
63% to 72%. 
Flow cytometry analysis 
The percentage of lamina propria CD4+CD25+FOXP3+ lymphocytes was analyzed 
by flow cytometry. LPL (2 x 105) were incubated with FITC, PE, PerPC or APC conjugated 
mAbs to human CD4, CD25, CD45 or with control isotypes (BD Biosciences, Le Pont de 
Claix, France) for 20 minutes at 4°C. For intracellular FOXP3 detection, cells were fixed, 
permeabilized using Human FOXP3 Buffer Set (BD Biosciences) and labelled with PE-
conjugated anti-human or control isotype (BD Biosciences). Analyses were performed with a 
BD LSRII flow cytometer using the CELLQuest software (BD Biosciences). As lamina 
propria preparations can be contaminated by some epithelial cells, percentages of 
CD4+CD25+FOXP3+ lymphocytes were determined in the gate of hematopoietic cells 
labeled by the pan-anti-CD45 antibody.  
Functional analysis  
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The suppressive functions of peripheral Tregs were tested in co-culture experiments in 
RPMI 1640 medium supplemented with 10% AB human serum (Sigma, St Louis, MO), 1% 
sodium pyruvate, 1% non essential aminoacids, 1% Hepes buffer, 5 x 10-5 M/l β-
mercaptoethanol and 40 µg/ml gentamycin, (Invitrogen, Cergy Pontoise, France). IEL, CD25- 
LPL and peripheral CD4+CD25- T subsets (105/well) were plated on 96-well plates coated 
with anti-CD3 antibodies (UCHT1, BD Biosciences) at 2µg/ml and added with 1 or 0.25 x105 
peripheral Tregs per well in a final volume of 200µl for 5 days. In most experiments 
cocultures were performed in autologous conditions. In two experiments, heterologous Tregs 
from controls or active CD were co-cultured with IEL, CD25- LPL and peripheral 
CD4+CD25- T subsets (105/well) from active CD and controls, respectively.   
Proliferative responses were assessed by measuring the uptake of [3H] thymidine 
(Amersham, Saclay, France) 18 hours after adding 0.4µCi/well. IFN-γ production was 
analyzed on supernatants of cells using Human IFN-γ ELISA Set (BD Biosciences) according 
to manufacturer’s instructions.  
Analysis of FOXP3 mRNA expression by real time RT-PCR 
 
Total RNA was extracted from duodenal biopsies using RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s procedure. The extracted RNA was then reverse transcribed 
using the Murine-Mooloney Leukemia Virus (MMLV) reverse transcriptase and random 
hexamers (Promega) according to standard procedure. FOXP3 mRNAs were quantified by 
real time PCR using available gene expressed assay® and Taqman PCR Master Mix (Applied 
Biosystems). Amplification was performed in cycles of denaturation at 95°C for 15 seconds 
and annealing and extension at 60°C for 1 minute using an ABI PRISM 7500 sequence 
detection system. Data were normalized referring to the expression of an endogenous gene 
RPLP0 (ribosomal Protein, Large, PO) by calculating 2 –∆CT, with ∆CT the difference in 
threshold cycles for target and reference.  
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Statistical Analysis 
Data obtained from the different groups of patients and healthy controls were 
compared by the non parametric Mann-Whitney U test. Statistical significance was assigned 
to a value of p < 0.05. 
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RESULTS AND DISCUSSION 
CD4+CD25+FOXP3+ T cells are increased in the lamina propria of active CD patients 
Real-time PCR analysis of intestinal biopsies demonstrated a significant increase in 
FOXP3 mRNA levels in active CD compared to controls (p<0.0001) and patients on a gluten-
free diet (p<0.01) (Figure 1A). Consistent with this finding, multicolor flow cytometry 
analysis showed a significantly higher percentage of CD4+CD25+FOXP3+ T lymphocytes 
among lamina propria CD45+ cells isolated from active CD patients than from controls 
(p=0.005) (Figure 1, panels B and C). In contrast, the percentage CD4+CD25+FOXP3+ 
lymphocytes remained comparable in peripheral blood CD45+ cells from CD and controls (p> 
0.05) (Figure 1B). The increased proportion of lamina propria lymphocytes with a Treg 
phenotype is in keeping with previous reports in CD (12-15) and argues against the 
hypothesis that a defect in the recruitment or in the de novo generation of intestinal Tregs may 
play a part in the pathogenesis of CD. These results are also consistent with very recent data 
showing that increased numbers of functional Tregs can be isolated from the lamina propria 
of patients with active CD (23).   
Intestinal effector T cells fail to respond to regulatory T cells in CD patients. 
The contrast between the intestinal expansion of CD4+CD25+FOXP3 T cells and the 
rupture of tolerance to dietary gluten in the intestine of active CD suggested that the latter 
cells may be impaired in their capacity to down-regulate local effector T cell functions or, 
conversely, that effector T cells may fail to respond to Tregs. To test whether intestinal 
lymphocytes from patients with CD were responsive or not to the suppressive effects of 
regulatory lymphocytes, blood samples and duodenal biopsies were obtained from 9 celiac 
disease patients and 9 controls. Peripheral blood CD4+CD25+ T cells (T regs) were then 
separated from CD4+CD25- peripheral lymphocytes (PBL) while IEL and LPL were isolated 
from endoscopic biopsies and CD25+ T cells removed from LPL to obtain a fraction of 
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CD25-LPL. The suppressive effects of autologous peripheral Tregs were tested on the 
proliferation and IFN-γ production of IEL, and of CD25- LPL and PBL stimulated with 
immobilized anti-CD3 antibody. With the idea in mind that the responses to Tregs may be 
variable within subsets of patients, we defined a “threshold of resistance” when the 
percentage of inhibition was below the 5th percentile of the control group. In two additional 
experiments, co-cultures were performed in heterologous conditions. 
In all tested controls and CD patients, CD25- PBL and LPL proliferated and produced 
IFN-γ in response to anti-CD3 stimulation (Figure 2 and Figure 3). In controls, these 
responses were efficiently inhibited by peripheral autologous Tregs (Figure 4). In contrast, 
suppression of proliferation and IFN-γ production was significantly less when LPL from CD 
patients were co-cultured with autologous peripheral Tregs (Figure 4). Moreover, the level of 
inhibition varied depending on the presence or not of intestinal lesions. Thus, in the 6 CD 
patients with villous atrophy, no suppression was observed in co-cultures of LPL with 
autologous T regs while suppression was detected in the three CD patients on GFD who had 
recovered a normal villous architecture (Figure 4). Interestingly, inhibition of proliferation 
and IFN-γ production of CD25- PBL by autologous Tregs was also impaired in active CD 
patients. In addition, in one CD patient who did not adhere strictly to GFD and remained with 
partial villous atrophy, Tregs were unable to inhibit IFN-γ production by peripheral CD25- 
PBL despite efficient inhibition of their proliferation (Figure 4).  
IEL proliferation and more particularly cytokine production in response to coated anti-
CD3 antibody varied between individuals, a variability previously ascribed to the lack of 
accessory signals in this in vitro assay (24) or to the release of immunosuppressive cytokines 
by epithelial cells (25). Yet, no significant difference was observed between groups of 
patients and controls (p> 0.05). (Figure 4 and data not shown).  In controls, the sensitivity 
of IEL to the inhibitory effect of autologous Tregs was variable and overall less than that of 
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PBL and LPL. Yet a striking finding was that, in all tested CD patients, IEL were completely 
resistant to the inhibitory effects of Tregs and the difference was highly significant when 
compared to controls (p = 0.0005). Altogether, these results indicated that, although the 
numbers of CD4+CD25+FOXP3+ T cells were increased in the intestine of active CD 
patients, these cells could not efficiently down-regulate effector T cell functions in the 
intestine but also in the periphery.  
The fact that the suppressor effect of Tregs on LPL and PBL was comparable in 
patients on GFD with normal histology and in controls suggested that the defect was not 
primary but secondary to the inflammatory process. Moreover, that Tregs from patients on 
GFD and with normal histology could suppress LPL and PBL but not IEL, rather pointed to 
an abnormal response of effector cells. It was, however, difficult to ascertain that the defect 
lied at the level of effector T cells, since immuno-suppression had been tested in autologous 
conditions. To confirm this hypothesis, co-cultures were performed in heterologous 
conditions. As shown in figure 5, Tregs from active CD patients could efficiently down-
regulate proliferation and IFN-γ production of PBL, LPL and IEL from controls. In contrast, 
Tregs from controls were unable to suppress effector T cells from active CD patients (Figure 
5) while they could efficiently suppress autologous PBL (data not shown). Altogether these 
results are in keeping with a recent article that shows that Tregs isolated from the lamina 
propria of patients with active CD are functional (23) and confirm that effector cells from 
patients with active CD fail to respond to Tregs either autologous or heterologous. We and 
others have previously shown that IL-15, a cytokine overproduced in CD patients, prevents 
the response of effector T cells to the suppressive effects of Tregs (20, 26). The lack of 
inhibitory effect of Tregs in CD may thus depend on the production of IL-15. In favor of this 
hypothesis, we observed that the serum levels of IL-15 were significantly increased in CD 
patients (4.9 pg/ml; 0.8 to 22.4 pg/ml) compared to controls (0.49 pg/ml; 0 to 2.79 pg/ml) 
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(p<0.001) (18). IL-15 is known to reverse the anergic state of Tregs and to allow their 
proliferation in response to anti-CD3 stimulation (27). The presence of circulating IL-15 may 
thus explain the small but significant proliferative response to anti-CD3 stimulation of 
peripheral Tregs from CD patients but not from controls (Figures 2 and 5 and data not 
shown). Similarly, a small secretion of IFN-γ by the latter cells was observed (Figures 3 and 
5 and data not shown). This finding is reminiscent of the recent demonstration by 
McClymont et al. that a subset of human Tregs from patients with type I diabetes produced 
IFN-γ while preserving their suppressive capacity (28). It will be interesting to define whether 
IL-15 participates in the appearance of this T cell subset since we have previously found that 
IL-15 was particularly increased in the serum of CD patients with type I diabetes (18). As 
already described (18), serum concentrations of IL-15 depended on disease activity (Figure 6) 
and were correlated with levels of anti-transglutaminase antibodies (data not shown). The 
fact that serum levels of IL-15 varied between patients may explain why two previous studies 
using co-culture of autologous peripheral Tregs and CD25-CD4+ T cells reported conflicting 
results when testing the immunosuppressive effect of peripheral T regs on autologous 
conventional T cells (10, 11). It is also noticeable that CD8+ T cells are much more sensitive 
to the effect of IL-15 and become thereby more easily unresponsive to the effect of Tregs 
after pre-incubation in IL-15 (18). IEL contain both CD8+ TcRαβ+ cells and TCRγδ+ cells 
also responsive to IL-15. The high sensitivity of IEL to IL-15 together with the fact that IL-15 
can remain increased in the epithelium of CD patients on GFD (16), might explain the lack of 
response of IEL to Treg suppression even in treated CD patients whose CD25- LPL and 
peripheral T cells responded to the inhibitory effect of autologous peripheral Tregs.  
In conclusion, we observe that peripheral Tregs from active CD display normal 
suppressive functions despite partial loss of their anergic state, a possible consequence of their 
in vivo exposure to IL-15. More strikingly, we demonstrate that intestinal but also peripheral 
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T lymphocytes become resistant to the suppressive effects of Tregs during active CD and that 
the defective response persists in IEL even after gluten eviction. Together with our previous 
studies showing that, due to IL-15 overexpression, intestinal T lymphocytes become 
unresponsive to the immunoregulatory cytokine TGF-β (29), these data provide a rationale for 
the loss of intestinal tolerance to gluten (30). Our demonstration of the inability of regulatory 
T cells of CD patients to control the expansion of lymphocytes using a polyclonal stimulus 
(anti-CD3 antibody) further suggests that such defect may underlie the loss of tolerance 
towards different antigens and the frequent occurrence of autoimmunity in CD (31, 32). The 
persistent resistance of IEL to Treg suppression in treated CD might also explain why the 
latter cells remain increased and abnormally activated despite GFD (33). Together with the 
anti-apoptotic effect of IL-15 (16, 34), the lack of effective retro-control of IEL activation 
may also, on the long term, promote the onset of IEL-derived lymphomas, a situation 
recapitulated in IL-15 transgenic mice which develop multi-organ lymphocytic infiltrates, 
aggressive autoimmune skin lesions and, ultimately, CD8+/NK T cell lymphoma or leukemia 
(35). Restoring the response of effector T cells to the regulatory effects of Tregs is likely 
central to prevent the onset of CD autoimmune complications. The normalization of LPL and 
PBL responses after GFD may explain why GFD can prevent the later complications. It will 
therefore be interesting to investigate whether unresponsiveness to Tregs persists or resumes 
despite GFD in patients developing refractory celiac disease. 
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FIGURE LEGENDS 
 
 
Figure 1: Intestinal CD4+CD25+FOXP3 T lymphocytes are increased in active CD.   
(A) Expression of FOXP3 mRNA in duodenal biopsies from 8 active CD patients, 8 CD 
patients on gluten free diet (GFD) and 7 healthy controls was analyzed by quantitative real-
time RT-PCR. Data were normalized referring to expression of ribosomal protein, large, PO 
(RPLPO). Results are expressed in arbitrary units as 2-∆CT, with ∆CT the difference in 
threshold cycles for target and reference. (B, C, D) Peripheral and lamina propria 
lymphocytes were isolated from 7 active CD patients, 6 CD patients on gluten free diet (GFD) 
and 6 healthy controls. The percentage of CD4+CD25+FOXP3+ lymphocytes among CD45+ 
peripheral (B) and intestinal (C) cells was assessed by flow cytometry. While percentages of 
CD4+CD25+FOXP3+ lymphocytes were comparable in peripheral blood of CD and controls 
(p>0.05), the percentage of CD4+CD25+FOXP3+ lymphocytes was significantly higher in 
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lamina propria of active CD or CD on GFD than of controls (p=0.005 and p=0.03, 
respectively). (D) Double staining of CD25 and FOXP3 in lamina propria CD4+ cells is 
shown in one representative donor from each study group. Percentages of CD25+FOXP3+ 
cells among CD45+CD4+ cells are indicated. 
 
 
 
Figure 2: Proliferation of peripheral and intestinal lymphocytes of CD patients is not 
efficiently inhibited by autologous peripheral T regs. 
 Purified intraepithelial lymphocytes (IEL), CD25- lamina propria lymphocytes (LPL), 
CD4+CD25- peripheral T lymphocytes (PBL) from CD patients and controls were stimulated 
with immobilized anti-CD3 antibody (2 µg/ml) in the presence or not of autologous 
CD4+CD25+ peripheral T lymphocytes (Tregs) a ratio 1:1 and 1:4 of regulatory to responsive 
T cells. To test whether Tregs were or not anergic, purified Tregs were activated alone in the 
presence of immobilized anti-CD3 (last black dotted histogram of each panel labeled T regs).  
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Proliferative responses were assessed by measuring the uptake of [3H] thymidine. Results of 
co-cultures at ratio 1:1 from one representative individual out of 3 active CD patients, 3 CD 
patients on GFD with villous atrophy, 3 CD patients on GFD without villous atrophy and 9 
controls are shown. Standard deviations from triplicates are represented. 
 
 
 
Figure 3: Interferon gamma secretion by peripheral and intestinal lymphocytes of CD 
patients is not efficiently inhibited by autologous peripheral T regs. 
 Purified intraepithelial lymphocytes (IEL), CD25- lamina propria lymphocytes (LPL), 
CD4+CD25- peripheral T lymphocytes (PBL) from CD patients and controls were stimulated 
as described in Figure 2. Supernatants from triplicate cultures were pooled and IFN-γ 
production was analyzed by ELISA. Results of co-cultures at ratio 1:1 from one 
representative individual out of 3 active CD patients, 3 CD patients on GFD with villous 
atrophy, 3 CD patients on GFD without villous atrophy and 9 controls are shown.  
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Figure 4: Global comparison of the responses of peripheral and intestinal lymphocytes 
to the suppressive effects of autologous Tregs in CD patients and control individuals. 
Inhibition of proliferation (A) and IFN-γ production (B) of IEL, CD25- lamina propria 
lymphocytes (LPL), CD4+CD25- peripheral T lymphocytes (PBL) by autologous 
CD4+CD25+ peripheral T cells was tested as in Figures 2 and 3. Histograms summarize data 
from co-cultures at ratio effector to Treg 1:1 in 9 controls and 9 CD patients depending on 
their diet and intestinal histology. In each histogram, the horizontal bar indicates the 
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percentage of inhibition corresponding to the 5th percentile of the controls used to define a 
“threshold of resistance”. 
 
Figure 5: Lack of suppression of effector lymphocytes from active CD patients by 
heterologous regulatory T cells from controls. 
IEL, CD25- LPL and peripheral CD4+CD25- T subsets from controls or from active CD 
patients were plated on 96-well plates coated with anti-CD3 antibodies at 2µg/ml and cultured 
with heterologous peripheral Tregs from active CD patients or from controls respectively at a 
ratio 1:1 in for 5 days. (A) Proliferative responses were assessed by measuring the uptake of 
[3H] thymidine. Standard deviations from triplicates are represented. (B) Supernatants from 
triplicate cultures were pooled and IFN-γ production was analyzed by ELISA. Results of one 
representative out of two independent experiments are shown.  
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Figure 6: Increase in IL-15 serum levels in active CD.  
 IL-15 serum levels were compared by ELISA in 20 controls, 10 patients with active celiac 
disease (CD) and 8 patients with CD on gluten free diet (GFD). 
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